Market›Health Care›Biotechnology›Biotechnology
METAGENOMI THERAPEUT

MGX

$1.50Feb 09, 2024 – Apr 24, 2026
Health CareBiotechnology$52M
MVM
+$0.6M
TD Variance
0.667

Every news event mapped to its market reaction — 29 events, 27 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2025-11-11-13.8%earningsSeeking AlphaMetagenomi GAAP EPS of -$0.55 beats by $0.03, revenue of $8.7M beats by $0.78M
2024-05-01-12.7%newsSeeking AlphaMetagenomi, Moderna terminate gene editing collaboration
2024-05-02-12.4%M&ASeeking AlphaJ.P. Morgan downgrades Metagenomi over Moderna deal termination
2024-11-14-11.8%earningsSeeking AlphaMetagenomi, Inc. GAAP EPS of -$0.51, revenue of $11.51M
2025-10-22-11.8%newsSeeking AlphaMetagenomi to use Amazon's chips for gene-editing tools
2024-08-15-11.0%earningsSeeking AlphaMetagenomi, Inc. GAAP EPS of -$0.29, revenue of $20M
2025-03-17-10.5%legalSeeking AlphaMetagenomi files for $250M mixed securities shelf
2025-03-17-10.5%earningsSeeking AlphaMetagenomi GAAP EPS of -$2.36 beats by $0.08, revenue of $52.29M beats by $0.59M
2024-03-27-7.6%newsSeeking AlphaMetagenomi reports FY results
2026-03-04+6.5%newsSeeking AlphaMetagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
2024-08-05+6.1%newsSeeking AlphaIPO Roundup: zSpace, Actuate Therapeutics and more
2024-05-15+6.0%earningsSeeking AlphaMetagenomi reports Q1 results
2026-03-05-5.6%earningsZacksMetagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
2026-03-05-5.6%earningsAssociated Press FinanceMetagenomi Therapeutics: Q4 Earnings Snapshot
2026-03-05-5.6%newsGlobeNewswireMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
2026-03-05-5.6%earningsSeeking AlphaMetagenomi GAAP EPS of -$2.36 in-line, revenue of $25.2M misses by $3.43M
2025-01-25-5.3%newsSeeking AlphaStargate Projects healthcare winners: AI-led biotechs and Metagenomi
2025-01-28-4.7%newsSeeking AlphaNeutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential
2025-08-12+4.6%earningsSeeking AlphaMetagenomi GAAP EPS of -$0.54 beats by $0.08, revenue of $8.51M beats by $0.79M
2025-05-14-3.1%earningsSeeking AlphaMetagenomi GAAP EPS of -$0.68, revenue of $4.12M
2026-02-23+3.0%newsGlobeNewswireMetagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
2026-02-12-2.5%newsSimply Wall St.Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?
2024-03-06+1.6%newsSeeking AlphaJefferies, BMO bullish on newly public Metagenomi
2026-04-16+1.3%newsGlobeNewswireMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
2026-04-02+0.9%newsSimply Wall St.Spotlight On 3 ASX Penny Stocks With Market Caps Under A$2B
2026-02-26-0.9%earningsZacksAmphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
2024-03-02+0.4%newsSeeking AlphaStocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps
2024-02-09—newsSeeking AlphaModerna-backed Metagenomi sees stock fall 31% after $94M IPO
2024-02-09—newsSeeking AlphaMetagenomi prices initial offering at $15 per share
tickerdossier.comtickerdossier.substack.com